RT Journal Article
SR Electronic
T1 Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.08.21254907
DO 10.1101/2021.04.08.21254907
A1 Tagreed A. Mazi
A1 Kamil Borkowski
A1 John W. Newman
A1 Oliver Fiehn
A1 Christopher L. Bowlus
A1 Souvik Sarkar
A1 Karen Matsukuma
A1 Mohamed R. Ali
A1 Dorothy A. Kieffer
A1 Yu-Jui Y. Wan
A1 Kimber L. Stanhope
A1 Peter J. Havel
A1 Valentina Medici
YR 2021
UL http://medrxiv.org/content/early/2021/04/10/2021.04.08.21254907.abstract
AB Nonalcoholic fatty liver disease (NAFLD) is a progressive condition that includes steatosis (NAFL) and nonalcoholic steatohepatitis (NASH). In the U.S., Hispanics (HIS) are afflicted with NAFLD at a higher rate and severity compared to other ethnicities. To date, the mechanisms underlying this disparity have not been elucidated. In this pilot study, we compared untargeted plasma metabolomic profiles for primary metabolism, complex lipids, choline and related compounds between a group of HIS (n =7) and White Caucasian (CAU, n =8) subjects with obesity and biopsy-characterized NAFL to ethnicity-matched lean healthy controls (n =14 HIS and 8 CAU). We also compared liver and plasma metabolomic profiles in a group of HIS and CAU subjects with obesity and NASH of comparable NAFLD Activity Scores, to BMI-matched NASH-free subjects in both ethnicities. Results highlight signs of metabolic dysregulation observed in HIS, independent of obesity, including higher plasma triglycerides, acylcarnitines, and free fatty acids. With NASH progression, there were ethnicity-related differences in the hepatic profile, including higher free fatty acids and lysophospholipids seen in HIS, suggesting lipotoxicity is involved in the progression of NASH. We also observed greater hepatic triglyceride content, higher plasma triglyceride concentrations and lower hepatic phospholipids with signs of impaired hepatic mitochondrial β-oxidation. These findings provide preliminary evidence indicating ethnicity-related variations that could potentially modulate the risk for progression of NALD to NASH.HighlightsHispanic subjects show signs of metabolic dysregulations independent of obesity.In nonalcoholic fatty liver, plasma metabolomic profiles are differentially altered between ethnicities.In nonalcoholic steatohepatitis, the hepatic lipidomic profiles are differentially altered between ethnicities.In Hispanics, nonalcoholic steatohepatitis shows higher triglycerides and lipotoxic lipids with signs of impaired hepatic mitochondrial β-oxidation.Our results indicate evidence of ethnicity-related variations in the pathogenesis of nonalcoholic fatty liver disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The National Institutes of Health (NIH)-West Coast Metabolomic Center (WCMC) grant number DK104770 (to V.M.), NIH-National Heart, Lung and Blood Institute 1R01 HL09133 (to P.H.) and 1R01 HL107256 (to P.H.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and WCMC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board at the University of California, Davis (protocol # 856052).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study details are available on The Metabolomics Workbench (http://www.metabolomicsworkbench.org), ID number (ST000977).http://www.metabolomicsworkbench.org ACAcylcarnitineCAUWhite CaucasiansCECholesteryl esterCerCeramidecPLA2Cytosolic phospholipases A2CSH-QTOF MSCharged surface hybrid column/quadrupole time of flight mass spectrometerDGDiglycerideDNLDe novo lipogenesisFDRFalse discovery rateFFAFree fatty acidGC-TOF MSGas chromatography/time-of-flight mass spectrometryHCHealthy controlHILIC-QTOF MS/MSHydrophilic interaction liquid chromatography/quadrupole time of flight mass spectrometerHISHispanicsKEGGKyoto Encyclopedia of Genes and GenomesLPCLysophosphatidylcholineLPELysophosphatidylethanolamineMUFAMonounsaturated fatty acidNAFLSteatosisNAFLDNonalcoholic fatty liver diseaseNASThe NAFLD Activity ScoreNASHNonalcoholic steatohepatitisNASH-CRNThe NASH Clinical Research NetworkPCPhosphatidylcholinePCAPrincipal component analysisPEPhosphatidylethanolaminePLPhospholipidPLS-DAPartial least square-discriminant analysisPUFAPolyunsaturated fatty acidSAMeS-Adenosyl-L-methionineSFASaturated fatty acidSMSphingomyelinTGTriglycerideTMAOTrimethylamine N-oxideVIPVariable importance in projection0-NASHNonalcoholic steatohepatitis-freeΔ-5 desaturaseFatty acid desaturase-1Δ-9 desaturaseStearoyl-CoA desaturase.